Cabozantinib resolves bone scans in tumor-naïve mice harboring skeletal injuries

Molecular Imaging

Volumn 13, Issue 8, 2014, Pages

  Doran, Michael G ^a   Spratt, Daniel E ^a   Wongvipat, John ^a   Ulmert, David ^a   Carver, Brett S ^a   Sawyers, Charles L ^a   Evans, Michael J ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; DISEASES; ENZYMES; MAMMALS; PARTICLE BEAMS; RADIOISOTOPES; SINGLE PHOTON EMISSION COMPUTED TOMOGRAPHY; SODIUM FLUORIDE; UROLOGY;

BONE REMODELING; POSITRON EMISSION; PROSTATE CANCERS; RECEPTOR TYROSINE KINASE; SELECTIVE INHIBITORS; SINGLE PHOTON EMISSION; THYROID CANCERS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR;

TUMORS;

ANILIDE; AXITINIB; CABOZANTINIB; CRIZOTINIB; FLUORINE; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; MEDRONATE TECHNETIUM TC 99M; PROTEIN KINASE INHIBITOR; PYRAZOLE DERIVATIVE; PYRIDINE DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ANIMAL; BONE REGENERATION; DRUG EFFECTS; FRACTURES, BONE; MOUSE; POSITRON EMISSION TOMOGRAPHY; PROCEDURES; SCINTISCANNING; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ANILIDES; ANIMALS; BONE REGENERATION; FLUORINE RADIOISOTOPES; FRACTURES, BONE; IMIDAZOLES; INDAZOLES; MICE; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; RADIOPHARMACEUTICALS; TECHNETIUM TC 99M MEDRONATE; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84907695265     PISSN: 15353508     EISSN: 15360121     Source Type: Journal    
DOI: 10.2310/7290.2014.00026     Document Type: Article

References (20)

1. Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10:2298-308, doi:10.1158/1535-7163.MCT-11-0264.
2. Bowles DW, Kessler ER, Jimeno A. Multi-targeted tyrosine kinase inhibitors in clinical development: focus on XL-184 (cabozantinib). Drugs Today 2011;47:857-68.
3. Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29:2660-6, doi:10.1200/JCO.2010.32.4145.
4. Sherman SI. Lessons learned and questions unanswered from use of multitargeted kinase inhibitors in medullary thyroid cancer. Oral Oncol 2013;49:707-10, doi:10.1016/j.oraloncology.2013.03.442.
5. Dai J, Zhang H, Karatsinides A, et al. Cabozantinib inhibits prostate cancer growth and prevents tumor-induced bone lesions. Clin Cancer Res 2014;20:617-30, doi:10.1158/1078-0432.CCR-13-0839.
6. Lee RJ, Saylor PJ, Michaelson MD, et al. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases. Clin Cancer Res 2013;19:3088-94, doi:10.1158/1078-0432.CCR-13-0319.
7. Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial. J Clin Oncol 2013;31:412-9, doi:10.1200/JCO.2012.45.0494.
8. Dayyani F, Gallick GE, Logothetis CJ, Corn PG. Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 2011;103:1665-75, doi:10.1093/jnci/djr362.
9. Brown MS, Chu GH, Kim HJ, et al. Computer-aided quantitative bone scan assessment of prostate cancer treatment response. Nucl Med Commun 2012;33:384-94, doi:10.1097/MNM.0b013e3283503ebf.
10. Nguyen HM, Ruppender N, Zhang X, et al. Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PloS One 2013;8:e78881, doi:10.1371/journal.pone.0078881.
11. Timofeevski SL, McTique MA, Ryan K, et al. Enzymatic characterization of c-Met receptor tyrosine kinase oncogenic mutants and kinetic studies with aminopyridine and triazolopyrazine inhibitors. Biochemistry 2009;48:5339-49, doi:10.1021/bi900438w.
12. Liu G, Rugo HS, Wilding G, et al. Dynamic contrast-enhanced magnetic resonance imaging as a pharmacodynamic measure of response after acute dosing of AG-013736, an oral angiogenesis inhibitor, in patients with advanced solid tumors: results from a phase I study. J Clin Oncol 2005;23:5464-73, doi:10.1200/JCO.2005.04.143.
13. Wong KK, Piert M. Dynamic bone imaging with 99mTc-labeled diphosphonates and 18F-NaF: mechanisms and applications. J Nucl Med 2013;54:590-9, doi:10.2967/jnumed.112.114298.
14. Aleman J, Girotra M, Farooki A. Effects of tyrosine kinase inhibitors on bone metabolism. Endocr Relat Cancer 2014. DOI:10.1530/ERC-12-0400.
15. Saylor PJ, Mahmood U, Kunawudhi A, et al. Multitargeted tyrosine kinase inhibition produces discordant changes between 99mTc-MDP bone scans and other disease biomarkers: analysis of a phase II study of sunitinib for metastatic castration-resistant prostate cancer. J Nucl Med 2012;53:1670-5, doi:10.2967/jnumed.112.105007.
16. Dror Michaelson M, Regan MM, Oh WK, et al. Phase II study of sunitinib in men with advanced prostate cancer. Ann Oncol 2009;20:913-20, doi:10.1093/annonc/mdp111.
17. Knudsen BS, Gmyrek GA, Inra J, et al. High expression of the Met receptor in prostate cancer metastasis to bone. Urology 2002;60:1113-7, doi:10.1016/S0090-4295(02)01954-4.
18. Varkaris A, Corn PG, Gaur S, et al. The role of HGF/c-Met signaling in prostate cancer progression and c-Met inhibitors in clinical trials. Expert Opin Invest Drugs 2011;20:1677-84, doi:10.1517/13543784.2011.631523.
19. Pisters LL, Troncoso P, Zhau HE, et al. c-Met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995;154:293-8, doi:10.1016/S0022-5347(01)67297-5.
20. Cho YT, Chan CC. Cabozantinib-induced hand-foot skin reaction with subungual splinter hemorrhages and hypertension: a possible association with inhibition of the vascular endothelial growth factor signaling pathway. Eur J Dermatol 2013;23:274-5.